Acute Myocardial Infarction (AMI)
AMI 30-Day All-Cause Risk Adjusted Readmissions (Medicare 65+)
2020 = YTD June 2020
AMI Mortality Performance
2020 = YTD June 2020
Premier Healthcare Database is one of the most comprehensive electronic healthcare databases, which has been utilized by the pharmaceutical and device industries, academia, healthcare insurers and healthcare policy makers for clinical, financial and outcomes analyses. (“Expected readmissions” is based on Premier’s Standard Practice Risk Methodology).
Patient Transfers
Direct admission • Transfer • Specialized transport
One Call 24/7 I Adult: 703-776-5905 I Pediatric: 877-900-9543
Diagnostic Catheterization
| Facility | 2020 |
|---|---|
| Inova Fairfax Medical Campus | 1,758 |
| Inova Alexandria Hospital | 1,023 |
| Inova Loudoun Hospital Schaufeld Family Heart Center | 650 |
| Inova Heart and Vascular Institute | 3,431 |
2020 = rolling 4Q, ending Q2 2020
Interventional Cardiology
Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.
Electrophysiology
| Ablation Volumes | 2020 |
|---|---|
| SVT Ablation | 574 |
| VT (Endocardial and Epicardial) Ablation | 137 |
| Afib | 590 |
| Ablation Procedures (Total) | 1,301 |
2020 = rolling 4Q, ending Q2 2020
| Device Implant Volumes | 2020 |
|---|---|
| Pacemakers | 808 |
| ICDs | 432 |
| Biventricular | 167 |
| Dual and Single Chamber | 244 |
| Subcutaneous | 21 |
| Watchman™ | 75 |
2020 = rolling 4Q, ending Q2 2020
Lead Extraction for Cardiovascular Implantable Electronic Devices: 52
%20(1).jpg)
Accredited for:
- Testing and Ablation
- Device Implantation
- Chronic Lead Extraction
Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.
Refer a Patient
Cardiac Surgery
 |
Society of Thoracic Surgery highest rating for quality of Coronary Artery Bypass Surgery 2016, 2017, 2018, 2019, 2020 |
Society of Thoracic Surgery highest rating for quality of Aortic Valve Replacement + CABG 2017, 2018, 2019, 2020 |
Society of Thoracic Surgery highest rating for quality of MVRR + CABG 2017-2019 |
CABG Combined Volume
2020 = rolling 4Q, ending Q2 2020
Pure CABG Mortality
2020 = rolling 4Q, ending Q2 2020
*2020 STS Benchmark unavailable – repeats 2019 STS Benchmark
Post-Op Blood Products Used
2020 = rolling 4Q, ending Q2 2020
*2020 STS Benchmark unavailable – repeats 2019 STS Benchmark
Intra-Op Blood Products Used
2020 = rolling 4Q, ending Q2 2020
*2020 STS Benchmark unavailable – repeats 2019 STS Benchmark
Total Surgical Valve Volumes
2020 = rolling 4Q, ending Q2 2020
Isolated Surgical Valve Procedures
| 2018 | 2019 | 2020 | |
|---|---|---|---|
| Isolated Aortic Valve Replacement | 51 | 46 | 38 |
| Isolated Mitral Valve Replacement | 37 | 37 | 30 |
| Isolated Mitral Repair | 37 | 48 | 46 |
2020 = rolling 4Q, ending Q2 2020
Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.
Refer a Patient
Structural Heart
New Clinical Trial Offers Treatment for Ticuspid Valve Regurgitation
TAVR Median Postprocedure Length of Stay
2020 = rolling 4Q, ending Q2 2020
TAVR 30-Day Mortality
2020 = rolling 4Q, ending Q2 2020
TAVR vs. Isolated AVR Cases
2020 = rolling 4Q, ending Q2 2020
Mitral Valve Repair Procedures Using MitraClip®
MitraClip: 2020 = rolling 4Q, ending Q2 2020
Minimally Invasive PFO Closure 2020: 83
2020 annualized from YTD January – October data
Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.
Refer a Patient
703-776-3135 I valve@inova.org
inovaheart.org/structuralheart
Inova Lung Services
"COVID-19 is a challenge of a lifetime. No one expected it, no one wanted it. The training and background of researchers at Inova prepared us for this moment. It is a privilege to lead teams who have been primed to pivot and tackle this new disease the way Inova has." – Steven Nathan, MD, FCCP, Medical Director, Inova Advanced Lung Disease and Lung Transplant Program
Patients Folllowed (n = 1,746), November 2019 – November 2020
Lung Transplant Volume: 24
Heart – Lung Transplant Volume: 12020 annualized from YTD January – October data
Lung Transplant Survival – Adult
| Observed | US Average | |
|---|---|---|
| Adult Patient Survival (1 year) | 89.75 | 88.89 |
SRTR August 2020 report
Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.
Refer a Patient
Cardiac and Respiratory Failure
ECMO
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Days of Support | 616 | 740 | 848 | 1,047 | 1,485 |
| Hours of Support | 14,018 | 16,901 | 19,269 | 23,797 | 33,949 |
| Pediatric ECMO Runs | 9 | 12 | 8 | 20 | 18 |
| Adult ECMO Runs | 57 | 68 | 83 | 93 | 124 |
| Total ECMO Runs | 66 | 80 | 91 | 113 | 142 |
2020 = rolling 4Q, ending in Q2 2020
Impella® Volumes and Cardiogenic Shock Activations
| 2018 | 2019 | 2020 | |
|---|---|---|---|
| Impella Volume | 110 | 100 | 90 |
| Shock Team Activations | 158 | 222 | 216* |
2020 annualized from YTD January - July data
*Due to COVID-19 demands and patient volume, some cardiogenic shock transfers were declined March – June 2020.
Cardiogenic Shock Patient Survival
Learn more about Inova’s Cardiogenic Shock Program at inovaheart.org/CS
Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.
Learn More
Inova Fairfax Medical Campus Receives ELSO Award for Excellence in Life Support
A Dramatic Delivery Showcases Inova’s Team Approach
Advanced Heart Failure
VAD and Heart Transplant Volumes
| 2020 | |
|---|---|
| VAD Volume – Durable Devices | 19 |
| Heart Transplant Volume | 43 |
| Heart - Lung Transplant | 1 |
2020 annualized from November YTD data
The Joint Commission Gold Seal of Approval® for Ventricular Assist Device
Heart Transplant Survival
| 2020 | Expected | Observed | HR Index |
|---|---|---|---|
| Graft Survival (1 year) | 90.20% | 92.74% | .77 |
| Patient Survival (1 year) | 90.45% | 92.74% | .79 |
SRTR August 2020 Report
Post-Implant Survival
Intermacs Q2 2020 Primary Overall Survival
Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.
Refer a Patient
703-776-6453 I heartfailure@inova.org
inovaheart.org/AHF
Learn More
PYP Imaging Reveals Cardiac Amyloidosis as a More Prevalent Cause of Heart Failure
Congenital Heart Disease
Thanks to advances in pediatric cardiac care, there is a growing population of adults with congenital heart disease who previously might not have survived childhood. Established in 1994 as a partnership between Inova Children’s Hospital and IHVI, Inova’s Adult Congenital Heart Disease (ACHD) Program was one of the first such programs in the country. Today, the ACHD Program provides complete continuity of care for patients with a variety of congenital heart defects, including those complicated by heart rhythm problems, heart failure and pulmonary hypertension.
The ACHD Program also partners with Inova Women’s Hospital to achieve the safest delivery possible for mothers with congenital heart defects and their babies. The ACHD Clinic is located in the Advanced Disease Management Clinic, on the Inova Fairfax Medical Campus. This provides patients seamless access to the collective expertise of Inova’s highly skilled pediatric and adult specialists in a single location.
Areas of specialization cover the full range of IHVI’s advanced cardiac therapies.
- Adult Congenital Cardiac Catheterization
- Adult Congenital Electrophysiology
- Adult Congenital Surgery
- Proactive Evaluation of Tetralogy Patients
- Maternal-Fetal Medicine
Neonatal Procedures
| 2020 | |
|---|---|
| Complex Cardiac Repairs | 26 |
| PDA Ligations – Premature Infant 3 | 3 |
| Total | 29 |
2020 annualized = rolling 4Q, ending Q2 2020
Pediatric Congenital Heart Surgery
| 2020 | |
|---|---|
| ASD | 6 |
| VSD | 11 |
| TOF | 9 |
| ASO | 3 |
| AVC (Complete, Partial) | 7 |
| PAPVR | 1 |
| TAPVR | 1 |
| COA (nonpump) | 6 |
| COA/Hypoarch | 8 |
| Glenn/Fontan | 8 |
| Systemic Pulmonary Shunt | 4 |
| Pacer/ICD | 18 |
| PVR/Conduit/RVOT procedure | 9 |
| AVR/Supra and Sub Valvar | 2 |
| MV Repair/Replacement | 3 |
| Tricuspid Valve | 0 |
| ECMO Cannulation | 9 |
| ECMO Procedures | 13 |
| PDA | 3 |
| NORWOOD/STAT 5 | 2 |
| Thoracic Procedure | 5 |
| Anomalous Coronary Surgery | 5 |
| Other STAT Categories | 8 |
| Other Cardiac Nonpump | 57 |
| Total | 198 |
2020 annualized = rolling 4Q, ending Q2 2020
For more information about the Pediatric Heart Center at Inova Children’s Hospital, visit: inovachildrens.org/heart
Adult Congenital Heart Surgery
| 2020 | |
|---|---|
| ASD | 4 |
| AVR/ASAA/Sub AS | 3 |
| MVR | 2 |
| PVR | 2 |
| PAPVR | 2 |
| VSD | 0 |
| AVC (Partial, Transitional) | 0 |
| Anomalous Coronary Surgery | 4 |
| Other | 11 |
| Total | 28 |
2020 annualized = rolling 4Q, ending Q2 2020
Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.
Refer a Patient
Adult Congenital Heart Program I 703-776-3599
Pediatric Congenital Heart Program I 703-776-4428
Fetal Congenital Heart Program I 703-776-6371
inovaheart.org/CHD
Vascular Services
Vascular Procedure Volumes
| 2020 | |
|---|---|
| Carotid Endarterectomy | 171 |
| Carotid Artery Stent | 6 |
| TCAR | 26 |
| Carotid Total |
203 |
| EVAR | 77 |
| TEVAR | 37 |
| Open AAA | 10 |
| Aneurysm Total | 124 |
| PVI | 225 |
| Bypass | 117 |
| Lower Extremity Total | 342 |
2020 = rolling 4Q, ending Q2 2020
Patient and procedural volumes for 2020 were impacted by a temporary suspension of elective procedures due to COVID-19 beginning in March through the end of May and the nationwide trend of decreased demand for services throughout the pandemic.
Learn More
Transforming Abdominal Aortic Aneurysm Care with the Alto™ Abdominal Stent Graft System
Transcarotid Artery Revascularization for High-Risk Patients with Carotid Artery Disease
Venous Arterialization Offers Limb-Saving Treatment for CLI
Refer a Patient
